Investor events Upcoming Events May 7, 2026 5:00 PM EDT Nektar Therapeutics Q1 2026 Financial Results Click here for webcast Add to Outlook Add to Google Calendar Archived Events Apr 20, 2026 8:00 AM EDT Analyst and Investor Event with Alopecia Areata Experts Click here for webcast Supporting Materials Analyst and Investor Event with Alopecia Areata Experts Presentation 3.9 MB Mar 12, 2026 5:00 PM EDT Nektar Therapeutics Q4 2025 Financial Results Click here for webcast Mar 4, 2026 9:10 AM EST TD Cowen 46th Annual Health Care Conference Click here for webcast Supporting Materials TD Cowen 46th Annual Health Care Conference Presentation 3.1 MB Feb 10, 2026 8:00 AM EST Nektar to Hold Conference Call to Discuss Topline Results from the 36-Week Maintenance Period for its REZOLVE-AD Phase 2b Study of Rezpegaldesleukin in Atopic Dermatitis Click here for webcast Supporting Materials Phase 2b REZOLVE-AD: Topline Results from 36-Week Maintenance Period 2.9 MB Dec 16, 2025 8:00 AM EST Nektar Therapeutics Analyst and Investor Event To Discuss REZOLVE-AA Topline Results Click here for webcast Supporting Materials Phase 2b REZOLVE-AA Topline Results from 36-Week Induction Treatment Period 4.6 MB Nov 20, 2025 11:00 AM GMT Jefferies Global Healthcare Conference in London Click here for webcast Contact IR Print Page RSS Email Alerts
Upcoming Events May 7, 2026 5:00 PM EDT Nektar Therapeutics Q1 2026 Financial Results Click here for webcast Add to Outlook Add to Google Calendar Archived Events Apr 20, 2026 8:00 AM EDT Analyst and Investor Event with Alopecia Areata Experts Click here for webcast Supporting Materials Analyst and Investor Event with Alopecia Areata Experts Presentation 3.9 MB Mar 12, 2026 5:00 PM EDT Nektar Therapeutics Q4 2025 Financial Results Click here for webcast Mar 4, 2026 9:10 AM EST TD Cowen 46th Annual Health Care Conference Click here for webcast Supporting Materials TD Cowen 46th Annual Health Care Conference Presentation 3.1 MB Feb 10, 2026 8:00 AM EST Nektar to Hold Conference Call to Discuss Topline Results from the 36-Week Maintenance Period for its REZOLVE-AD Phase 2b Study of Rezpegaldesleukin in Atopic Dermatitis Click here for webcast Supporting Materials Phase 2b REZOLVE-AD: Topline Results from 36-Week Maintenance Period 2.9 MB Dec 16, 2025 8:00 AM EST Nektar Therapeutics Analyst and Investor Event To Discuss REZOLVE-AA Topline Results Click here for webcast Supporting Materials Phase 2b REZOLVE-AA Topline Results from 36-Week Induction Treatment Period 4.6 MB Nov 20, 2025 11:00 AM GMT Jefferies Global Healthcare Conference in London Click here for webcast
May 7, 2026 5:00 PM EDT Nektar Therapeutics Q1 2026 Financial Results Click here for webcast Add to Outlook Add to Google Calendar
Apr 20, 2026 8:00 AM EDT Analyst and Investor Event with Alopecia Areata Experts Click here for webcast Supporting Materials Analyst and Investor Event with Alopecia Areata Experts Presentation 3.9 MB
Mar 4, 2026 9:10 AM EST TD Cowen 46th Annual Health Care Conference Click here for webcast Supporting Materials TD Cowen 46th Annual Health Care Conference Presentation 3.1 MB
Feb 10, 2026 8:00 AM EST Nektar to Hold Conference Call to Discuss Topline Results from the 36-Week Maintenance Period for its REZOLVE-AD Phase 2b Study of Rezpegaldesleukin in Atopic Dermatitis Click here for webcast Supporting Materials Phase 2b REZOLVE-AD: Topline Results from 36-Week Maintenance Period 2.9 MB
Dec 16, 2025 8:00 AM EST Nektar Therapeutics Analyst and Investor Event To Discuss REZOLVE-AA Topline Results Click here for webcast Supporting Materials Phase 2b REZOLVE-AA Topline Results from 36-Week Induction Treatment Period 4.6 MB
